NovAliX announced it has entered into a multi-target integrated drug discovery collaboration with Teijin Pharma Limited.
Within the alliance, the companies will collaborate to develop novel drug candidates against multiple targets across different therapeutic areas. NovAliX will initially use its protein biochemistry expertise in combination with its biophysical technology platform. NovAliX will apply its Graffinity SPR-based screening technology for the identification of novel chemotypes, and then engage its nano-MS technology for further characterization of selected small molecule hit structures.
Under the terms of the agreement, NovAliX will receive technology access fees as well as further research funding payments. Financial details of the transaction were not disclosed.
Release Date: Jan. 12, 2012